101 -5 (79) 2025 - Mamajonov Z.A., Mamatova I.Yu. - THE ROLE OF ADENOSINE RECEPTORS IN GLIOBLASTOMA

THE ROLE OF ADENOSINE RECEPTORS IN GLIOBLASTOMA

Mamajonov Z.A. - Andijan State Medical Institute

Mamatova I.Yu. - Andijan State Medical Institute

Ulugbekova G.Zh. - Andijan State Medical Institute

Resume

Glioblastoma (GB) is the most aggressive and difficult to treat form of malignant brain tumors. In recent years, there has been increasing interest in studying the role of adenosinergic signaling in the pathogenesis of GB. Adenosine, released in large quantities in the tumor microenvironment, interacts with four types of purinergic receptors — A1, A2A, A2B, and A3. These receptors regulate a wide range of biological processes, including cell proliferation, angiogenesis, immune suppression, and therapy resistance. Particularly significant in the context of glioblastoma are the A2A and A2B receptors, which contribute to the immunosuppressive environment by inhibiting the activity of cytotoxic lymphocytes and promoting macrophage polarization towards the M2 phenotype.The blockade of adenosine receptors, particularly A2A, is considered a promising therapeutic strategy that can enhance the effectiveness of immunotherapy and chemotherapy. This article discusses the molecular mechanisms of action of adenosine and its receptors in the tumor environment, their impact on the heterogeneity and invasiveness of glioblastoma, and addresses modern approaches to targeted therapy aimed at modulating adenosine signaling.

Keywords: glioblastoma, adenosine, adenosine receptors, A2A, A2B, immunosuppression, targeted therapy, tumor microenvironment.

First page

512

Last page

514

For citation:Mamajonov Z.A., Mamatova I.Yu., Ulugbekova G.Zh. - THE ROLE OF ADENOSINE RECEPTORS IN GLIOBLASTOMA //New Day in Medicine 5(79)2025 512-514 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

  1. Burnstock G. Purinergic signalling: past, present and future. Braz J Med Biol Res. 2009 Jan;42(1):3-8. doi: 10.1590/s0100-879x2008005000037. Epub 2008 Oct 3. PMID: 18853040.
  2. Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, Kershaw MH, Stagg J, Darcy PK. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. Cancer Immunol Res. 2015 May;3(5):506-17. doi: 10.1158/2326-6066.CIR-14-0211. Epub 2015 Feb 11. PMID: 25672397.
  3. Debom GN, Rubenich DS, Braganhol E. Adenosinergic Signaling as a Key Modulator of the Glioma Microenvironment and Reactive Astrocytes. Front Neurosci. 2022 Jan 5;15:648476. doi: 10.3389/fnins.2021.648476. PMID: 35069091; PMCID: PMC8766410.
  4. Fishman P, Bar-Yehuda S, Synowitz M, Powell JD, Klotz KN, Gessi S, Borea PA. Adenosine receptors and cancer. Handb Exp Pharmacol. 2009;(193):399-441. doi: 10.1007/978-3-540-89615-9_14. PMID: 19639290; PMCID: PMC3598010.
  5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330. PMID: 15758009.

    file

    download